CD276 and small cell lung carcinoma: Among 40 advanced pretreated solid tumor patients, the ORR was 35%, and the disease control rate (DCR) reached 85%, regardless of baseline B7-H3 expression levels. In 11 evaluable small cell lung cancer (SCLC) patients, the ORR was 63.6%, with all responses observed at the first disease assessment and a median time to response of 6 weeks. The DCR was 81.8%, with a median progression-free survival (PFS) of 4.7 months and a 3-month PFS rate of 72.7%.